A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Abemaciclib (Primary) ; Loperamide; Tamoxifen
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms nextMONARCH 1
- Sponsors Eli Lilly
- 24 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Jan 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Jun 2018.
- 11 Apr 2017 Planned End Date changed from 1 Aug 2019 to 1 May 2019.